Aurobindo Pharma shares fall after USFDA flags Eugia Unit III with OAI status
Eugia Pharma is Aurobindo Pharma’s wholly-owned subsidiary. The US drug regulator had inspected the Telangana-based facility from January 27 to February 6 and concluded it with 11 observations. It communicated the classification to the company on June 12, 2026.
What Is An OAI Status Classification by USFDA?
An OAI classification means significant regulatory violations were found at the unit and the agency is recommending a formal administrative or regulatory action.
While the facility can continue to sell the approved drugs, it will not get approvals for new drugs till the violations are addressed to the satisfaction of the regulator.
What Did Aurobindo Pharma Say To OAI Classification?
Aurobindo Pharma said there is no impact on its operations or financials due to the development.
On another note, earlier this month, Aurobindo Pharma inaugurated TheraNym, a dedicated biologics contract manufacturing organisation (CMO), marking its entry into the biologics contract manufacturing segment.
Is Aurobindo Pharma A Buy Or Sell?
28 analysts have coverage on Aurobindo Pharma, of which 19 have a “buy” rating, five have a “hold” rating, and four have a “sell” rating.
Shares of Aurobindo Pharma are trading 1.1% lower on Monday at ₹1,455.9. The stock has risen 22% so far in 2026, despite a 4% drop over the last one month.
Also Read: Four Pharma stocks should be on your radar today – Here are their key triggers
